Edition:
United States

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

6.14USD
12 Dec 2017
Change (% chg)

$3.79 (+161.28%)
Prev Close
$2.35
Open
$5.49
Day's High
$6.95
Day's Low
$5.15
Volume
8,474,954
Avg. Vol
116,256
52-wk High
$16.65
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Tuesday, 12 Dec 2017 04:01pm EST 

Dec 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL, 7 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Monday, 11 Dec 2017 04:21pm EST 

Dec 11 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS.PROTEOSTASIS THERAPEUTICS INC - 28-DAY STUDY CONTINUES TO CONFIRM SAFETY PROFILE OF PTI-428 IN THAT IT WAS GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - PTI-808 WAS FOUND TO BE GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - RESULTS OF PTI-428 MEET EFFICACY ENDPOINT IN 28-DAY STUDY IN CF PATIENTS ON BACKGROUND ORKAMBI.  Full Article

Proteostasis Therapeutics Q3 loss per share $0.56
Tuesday, 14 Nov 2017 05:40pm EST 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Tuesday, 31 Oct 2017 04:05pm EDT 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

Proteostasis Therapeutics files investigational NDA for PTI-808, cystic fibrosis potentiator
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Proteostasis Therapeutics Inc ::Proteostasis Therapeutics files investigational new drug application for PTI-808, cystic fibrosis potentiator.Proteostasis Therapeutics Inc says proteostasis plans to initiate a phase 1 study of PTI-808 in healthy volunteers in July.Proteostasis Therapeutics Inc - by end of June, co expects to report preliminary data from mad cohorts of two different CF patient populations.  Full Article

Proteostasis Therapeutics says files for mixed shelf of up to $125 mln
Wednesday, 7 Jun 2017 07:37am EDT 

June 7 (Reuters) - Proteostasis Therapeutics Inc :Says files for mixed shelf of up to $125 million - sec filing.  Full Article

Proteostasis Therapeutics reports Q4 loss per share $0.38
Thursday, 30 Mar 2017 04:30pm EDT 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics reports fourth quarter and year-end 2016 financial results and provides corporate update . Qtrly net loss per share attributable to common stockholders-basic and diluted $0.38 . Proteostasis Therapeutics Inc says plans for phase 1 trial, which will also investigate PTI-801 in cf patients, to run in U.S. and European sites . Proteostasis Therapeutics Inc says expects data from patients stable on Orkambi who have been dosed with PTI-801 for 14 days in second half of 2017 . Proteostasis - Expects cash, cash equivalents, short-term investments sufficient to fund operating expenses and capex requirements through Q2 of 2018 . Proteostasis Therapeutics Inc - Qtrly loss per share $0.38 .Q4 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S.  Full Article

Proteostasis Therapeutics says its CFO James Detore provided notice of his resignation from company, effective Feb 10
Wednesday, 1 Feb 2017 05:20pm EST 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics says its Chief Financial Officer James Detore provided notice of his resignation from company, effective February 10, 2017 . Proteostasis Therapeutics Inc - Company has commenced a search for a CFO replacement - SEC Filing .Proteostasis Therapeutics - Brett Hagen, controller, principal accounting officer since May 2016, to assume certain of Detore's duties on interim basis.  Full Article

Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock
Tuesday, 6 Sep 2016 06:21am EDT 

Proteostasis Therapeutics Inc :Files to say it is offering 4.3 million shares of its common stock.  Full Article

Proteostasis Therapeutics files for common stock offering
Thursday, 25 Aug 2016 05:36pm EDT 

Proteostasis Therapeutics Inc : Files for common stock offering of up to $60 million - SEC filing Source: (http://bit.ly/2bDxfUB) Further company coverage: [PTI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies

* PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS